Touchlight’s dbDNA™ Manufacturing Facility Receives World-First GMP License from MHRA
Touchlight, an innovation-driven Contract Development and Manufacturing Organisation (CDMO), today announced that its facility in Hampton UK has received GMP certification.
January 14, 2025
by PharmaSources
Early risers: life-changing medical scheme given legal revitalisation
Boost for patients with life-threatening conditions who require access to medicines not yet authorised for marketing.
February 3, 2022
by pharmatimes
Voxelotor for haemolytic anaemia treatment gains positive opinion
MHRA awards a positive scientific opinion for voxelotor–a once-daily tablet for the treatment of haemolytic anaemia.
January 27, 2022
by pharmatimes
UK MHRA grants approval to Pfizer’s oral antiviral for Covid-19
In a trial, Paxlovid, given within three days of symptom onset, lowered hospitalisation and death risk within 28 days by 89%.
January 4, 2022
by Pharmaceutical-Technology
MHRA grants approval for Pfizer’s oral COVID-19 antiviral pill
Pfizer’s Paxlovid has a success rate of nearly 90% as a prophylaxis treatment against severe COVID-19 when administered shortly after the patient has been infected with the virus.
January 4, 2022
by pharmatimes
COVID-19 vaccine should be offered to vulnerable children aged five to 11-years-old
Government vaccine advisers have said vulnerable primary school children should be offered a low-dose of a COVID-19 vaccine.
December 23, 2021
by pharmatimes
Northwest Biotherapeutics Receives MHRA Approval of License for GMP Manufacturing in UK
Enables the manufacturing of DCVax-L products to get under way at the Sawston facility.
December 22, 2021
by contractpharma
UK regulator publishes guidance on use of real-world data to support clinical trials
Two new guidance documents, the first in a series to published by the MHRA, outline considerations when planning a randomised clinical trial using real-world data.
December 20, 2021
by EuropeanPharmaceuticalReview
Health minister welcomes new treatments for COVID-19 patients
The treatments are being offered as an addition to vaccinations to maximise protection against COVID-19.
December 13, 2021
by PharmaTimes
UK’s MHRA grants authorisation for GSK-Vir Biotechnology’s Covid-19 drug
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for GSK and Vir Biotechnology’s investigational Covid-19 therapy, Xevudy (sotrovimab).
December 6, 2021
by Pharmaceutical-Technology
MHRA approves Xevudy (sotrovimab) to treat COVID-19
The Medicines and Healthcare products Regulatory Agency (MHRA) approve sotrovimab for people with mild to moderate COVID-19 infection and at least one risk factor for developing severe illness.
December 3, 2021
by EuropeanPharmaceuticalReview
MHRA approves for Epidyolex® (cannabidiol) for TSC seizure treatment
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
August 13, 2021
by europeanpharmaceuticalreview